This is the fourth ‘Request for Proposals’ (RFP) issued through the multi-year collaboration between Fast Forward and Merck KGaA to drive the commercial development of MS therapies.
Fast Forward will provide resources for underfunded academic institutions and seed-to-early-stage companies engaged in research concerning multiple sclerosis.
EMD Serono US Research vice president Steve Arkinstall said through the partnership the company hopes to expand its knowledge and understanding of MS to make new treatment options for people suffering with the disease.